Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1963 2
1964 2
1969 3
1970 2
1971 1
1972 1
1973 3
1974 2
1975 2
1976 1
1977 1
1978 2
1979 3
1980 4
1981 3
1982 3
1983 1
1984 1
1985 2
1986 4
1988 2
1991 1
1993 2
1994 1
1996 3
2001 1
2002 3
2003 1
2004 3
2006 2
2008 7
2009 6
2010 13
2011 14
2012 13
2013 15
2014 18
2015 24
2016 34
2017 32
2018 39
2019 32
2020 39
2021 29
2022 24
2023 43
2024 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

409 results

Results by year

Filters applied: . Clear all
Page 1
Japan-Multimodal Intervention Trial for the Prevention of Dementia: A randomized controlled trial.
Sakurai T, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, Kinoshita F, Kuzuya M, Lee S, Matsumoto N, Matsuo K, Michikawa M, Nakamura A, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Uchida K, Umegaki H, Wakayama S, Arai H; J‐MINT study group. Sakurai T, et al. Among authors: hirakawa a. Alzheimers Dement. 2024 Jun;20(6):3918-3930. doi: 10.1002/alz.13838. Epub 2024 Apr 22. Alzheimers Dement. 2024. PMID: 38646854 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: hirakawa a. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.
Mikamo H, Takahashi S, Yamagishi Y, Hirakawa A, Harada T, Nagashima H, Noguchi C, Masuko K, Maekawa H, Kashii T, Ohbayashi H, Hosokawa S, Maejima K, Yamato M, Manosuthi W, Paiboonpol S, Suganami H, Tanigawa R, Kawamura H; IVERMILCO Study Group. Mikamo H, et al. Among authors: hirakawa a. J Infect Chemother. 2024 Jun;30(6):536-543. doi: 10.1016/j.jiac.2023.12.012. Epub 2023 Dec 27. J Infect Chemother. 2024. PMID: 38154616 Free article. Clinical Trial.
Thrombosis and antiphospholipid antibodies in Japanese COVID-19: based on propensity score matching.
Oba S, Hosoya T, Kaneshige R, Kawata D, Yamaguchi T, Mitsumura T, Shimada S, Shibata S, Tateishi T, Koike R, Tohda S, Hirakawa A, Yoko N, Otomo Y, Nojima J, Miyazaki Y, Yasuda S. Oba S, et al. Among authors: hirakawa a. Front Immunol. 2023 Oct 16;14:1227547. doi: 10.3389/fimmu.2023.1227547. eCollection 2023. Front Immunol. 2023. PMID: 37908357 Free PMC article.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K. Koyama T, et al. Among authors: hirakawa a. Cancer Discov. 2023 Aug 4;13(8):1814-1825. doi: 10.1158/2159-8290.CD-23-0419. Cancer Discov. 2023. PMID: 37369013 Clinical Trial.
409 results